0000000000798300

AUTHOR

Karsten Witt

showing 2 related works from this author

Antagonizing dabigatran by idarucizumab in cases of ischemic stroke or intracranial hemorrhage in Germany—Updated series of 120 cases

2020

Background Idarucizumab is a monoclonal antibody fragment with high affinity for dabigatran reversing its anticoagulant effects within minutes. Thereby, patients with acute ischemic stroke who are on dabigatran treatment may become eligible for thrombolysis with recombinant tissue-type plasminogen activator (rt-PA). In patients on dabigatran with intracerebral hemorrhage idarucizumab could prevent lesion growth. Aims To provide insights into the clinical use of idarucizumab in patients under effective dabigatran anticoagulation presenting with signs of acute ischemic stroke or intracranial hemorrhage. Methods Retrospective data collected from German neurological/neurosurgical departments ad…

medicine.medical_specialtymedicine.drug_classmedicine.medical_treatmentMedizinAntibodies Monoclonal HumanizedAntithrombinsBrain IschemiaDabigatranGermanyInternal medicinemedicineHumansThrombolytic Therapyddc:610Ischemic StrokeRetrospective StudiesIntracerebral hemorrhagebusiness.industryAnticoagulantWarfarinIdarucizumabAtrial fibrillationThrombolysisVitamin K antagonistmedicine.diseaseDabigatranStrokeNeurologyCardiologybusinessIntracranial Hemorrhagesmedicine.drugInternational Journal of Stroke
researchProduct

Effect of high-frequency subthalamic neurostimulation on gait and freezing of gait in Parkinson's disease: a systematic review and meta-analysis.

2016

The aim of this meta-analysis was to summarize the short- and long-term effects of bilateral deep brain stimulation of the subthalamic nucleus (STN-DBS) on gait and freezing of gait (FOG) in Parkinson's disease and to detect predictors of post-stimulation outcome. A comprehensive review of the literature was conducted up to October 2015 using Medline Ovid databases for studies analyzing the effect of bilateral STN-DBS on FOG and/or gait. Sixteen studies with available data for the gait item (no. 29) of the Unified Parkinson's Disease Rating Scale (UPDRS) and six studies with the FOG item (no. 14) were included. Data were summarized for the following follow-up periods: 6-15, 24-48 and48 mont…

0301 basic medicinemedicine.medical_specialtyLevodopaDeep brain stimulationParkinson's diseasemedicine.medical_treatmentDeep Brain Stimulation03 medical and health sciences0302 clinical medicineGait (human)Physical medicine and rehabilitationRating scaleSubthalamic NucleusmedicineHumansNeurostimulationGaitGait Disorders Neurologicbusiness.industryParkinson Diseasemedicine.diseasenervous system diseasesSubthalamic nucleus030104 developmental biologyTreatment OutcomeNeurologyMeta-analysisPhysical therapyNeurology (clinical)business030217 neurology & neurosurgerymedicine.drugEuropean journal of neurology
researchProduct